Please ensure Javascript is enabled for purposes of website accessibility

3 Tremendously Promising Diabetes Drugs Potentially on the Way

By Keith Speights - Mar 26, 2017 at 9:03AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Diabetes patients could have new treatment options if Merck, Pfizer, Lexicon, Sanofi, and Novo Nordisk succeed with these three promising drugs.

Here's the scary thing about diabetes: Over 30 million Americans have it, with an additional 1.4 million new diagnoses each year. The disease is the seventh-highest cause of death in the U.S.

Those are concerning statistics, but there are also some numbers that provide hope. Over 170 new medicines are currently in development targeting treatment of diabetes and diabetes-related conditions. Here are three of the most promising diabetes drugs from five of the most innovative drugmakers in the world: Merck (MRK 1.37%), Pfizer (PFE -0.23%), Lexicon Pharmaceuticals (LXRX 4.30%), Sanofi (SNY 1.96%), and Novo Nordisk (NVO 0.19%).

Doctor writing "diabetes"

Image source: Getty Images.

1. Ertugliflozin

Merck and Pfizer are collaborating on development of ertugliflozin, an experimental drug for treating patients with type 2 diabetes. The drug could be approved in the U.S. later this year as a stand-alone treatment, in combination with Merck's Januvia, and in combination with metformin.

Ertugliflozin belongs to a class of medicines known as SGLT2 inhibitors. These drugs lower blood sugar by causing the kidneys to remove sugar from the body through the urine. Several SGLT2 inhibitors are already available, including Farxiga, Invokana, and Jardiance. 

Results from late-stage clinical studies conducted by Merck and Pfizer were very encouraging. Not only did ertugliflozin help lower blood sugar levels, but patients taking the experimental drug also experienced weight reduction and lower blood pressure levels. 

2. Sotagliflozin

Another promising SGLT inhibitor might not be too far behind ertugliflozin. Lexicon and Sanofi are evaluating sotagliflozin in late-stage studies. The drug could potentially reach the market within the next couple of years if all goes well.

Sotagliflozin inhibits SGLT1 and SGLT2 proteins. SGLT1 is responsible for glucose absorption in the gastrointestinal tract, while SGLT2 is responsible for glucose reabsorption by the kidney. Lexicon, which originally developed sotagliflozin, is focusing on clinical studies for type 1 diabetes, while Sanofi is handling clinical development and potential commercialization for type 2 diabetes. 

Lexicon reported positive results from the first two late-stage studies of sotagliflozin in treating type 1 diabetes in 2016, with significant reductions in patients' blood sugar levels. The company has one other late-stage study in progress for the indication; results should be available by mid-2017. Sanofi also has three additional clinical trials underway evaluating the drug in treating type 2 diabetes. 

3. Semaglutide

Novo Nordisk hopes to win regulatory approval for its newest diabetes drug, semaglutide, by Dec. 5, 2017. The pharmaceutical company submitted for approval in the U.S. and in Europe late last year.

Semaglutide targets type 2 diabetes by mimicking the action of the glucagon-like peptide-1 (GLP-1) receptor. GLP-1 stimulates the release of insulin and reduces glucagon, a hormone that increases blood sugar levels. If approved, semaglutide would join other GLP-1 receptor agonists such as Trulicity and Victoza. 

Late-stage studies found that semaglutide lowered blood sugar levels and resulted in weight reduction in patients taking the drug. In addition, semaglutide demonstrated reduction in cardiovascular risk compared to placebo. 

Into the future

An even more exciting diabetes treatment could be available in the future. Glucose-responsive insulin (GRI), also known as "smart insulin," holds the potential to detect blood sugar levels and automatically release the correct dosage to adjust those levels.

At least two of the companies already mentioned are developing glucose-responsive insulin products. Merck's MK-2640 is in early-stage testing. Sanofi has partnered with diabetes research group JDRF to develop glucose-responsive insulin. 

It will take several years before these products could be on the market, however. And there's always a risk that issues arise in the clinical-development or regulatory-approval processes. (By the same token, the possibility also exists that ertugliflozin, sotagliflozin, and/or semaglutide could stumble along the way.) However, the chances that diabetes becomes less scary in the future thanks to new treatments appear to be pretty good.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Pfizer Inc. Stock Quote
Pfizer Inc.
$52.31 (-0.23%) $0.12
Merck & Co., Inc. Stock Quote
Merck & Co., Inc.
$92.42 (1.37%) $1.25
Sanofi Stock Quote
$51.01 (1.96%) $0.98
Novo Nordisk A/S Stock Quote
Novo Nordisk A/S
$111.64 (0.19%) $0.21
Lexicon Pharmaceuticals, Inc. Stock Quote
Lexicon Pharmaceuticals, Inc.
$1.94 (4.30%) $0.08

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/05/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.